Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

Hepatology (Baltimore, Md.) - 1 Jul 2004

Marcellin Patrick, Mommeja-Marin Herve, Sacks Stephen L, Lau George K K, Sereni Daniel, Bronowicki Jean-Pierre, Conway Brian, Trepo Christian, Blum M Robert, Yoo Byung Chul, Mondou Elsa, Sorbel Jeff, Snow Andrea, Rousseau Franck, Lee Hyo-Suk

Abstract excerpt

Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure. Clevudine is a new pyrimidine analog with potent anti-hepatitis B virus (HBV) activity in vitro. A multicenter dose-escalation study evaluated clevudine at 10, 50, 100, and 200 mg once daily for 28 days. Eligible patients had HBV DNA levels of 3 x 10(6) copies/mL or more, had not undergone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Gene Dosage

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Predictive Value of Tests

Source

Identifiers

PMID: 15239097
DOI: 10.1002/hep.20257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.PMID 15239097Read ↗

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.Semantic proximity Read ↗

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.Semantic proximity Read ↗

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.Semantic proximity Read ↗

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Semantic proximity Read ↗

Clevudine: a potent inhibitor of hepatitis B virus<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].Semantic proximity Read ↗

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Semantic proximity Read ↗

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.Semantic proximity Read ↗

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.Semantic proximity Read ↗

Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B PatientsSemantic proximity Read ↗

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.Semantic proximity Read ↗

Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.